ストックスクリーナーアプリを入手
38.93
5.88%
-2.43
アフターアワーズ：
38.75
-0.18
-0.46%
前日終値:
$41.36
開ける：
$41.13
24時間の取引高:
1.55M
Relative Volume:
0.66
時価総額：
$6.65B
収益：
-
当期純損益:
$-354.30M
株価収益率:
-15.43
EPS:
-2.5234
ネットキャッシュフロー:
$-286.27M
1週間 パフォーマンス:
-2.09%
1か月 パフォーマンス:
+0.59%
6か月 パフォーマンス:
+8.41%
1年 パフォーマンス:
+240.89%
1日の値動き範囲:
$38.76
$41.30
1週間の範囲:
$38.76
$42.11
52週間の値動き範囲:
$10.38
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Compare COGT vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
38.93 | 6.91B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
BlackRock (COGT holder) discloses 8.0% ownership in Cogent Biosciences common stock - Stock Titan
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cogent Biosciences Inc (COGT) Cash Flow - TradingKey
COGT|Cogent Biosciences Inc|Price:40.450|Chg%:+0.690 - TradingKey
COGT|Cogent Biosciences Inc|Price:39.760|Chg%:-0.480 - TradingKey
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
COGT6232219 Bond Risk Profile - TradingView
COGT6232219 Bond Coupon Profile — Rate & Payments - TradingView
COGT6232219 Bond Profile — Key Metrics - TradingView
Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib - Yahoo Finance
Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Enterprise value to EBITDA forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation - Sahm
Price to book forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)? - Sahm
Cogent Biosciences (COGT) director takes options in lieu of cash - Stock Titan
Cogent Biosciences (COGT) Edges Higher, Tests Key Resistance Amid Sector TailwindsFlat Correction - dars.gov.et
Enterprise value to revenue forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing - Sahm
COGTCogent Biosciences Inc Forecast, Target Price - Finviz
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment - marketscreener.com
Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib - GuruFocus
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) - The Manila Times
Cogent Biosciences Announces Submission of New Drug - GlobeNewswire
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base - simplywall.st
Cogent Biosciences stock retreats after recent gains as bullish momentum consolidates - Traders Union
Cogent Biosciences stock edges lower with sideways action after Elevation Summit event - Traders Union
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT) - TradingView
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell Microcap Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 3000 Value Benchmark - marketscreener.com
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R - Moomoo
COGT Forecast — Price Target — Prediction for 2027 - TradingView
Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress - Insider Monkey
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? - Yahoo Finance
New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT) - Sahm
Trading Systems Reacting to (COGT) Volatility - Stock Traders Daily
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT) - The Globe and Mail
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences Inc (COGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
Cogent Biosciences Inc (COGT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):